Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03197012
Other study ID # 17455
Secondary ID NCI-2017-01886
Status Completed
Phase Early Phase 1
First received
Last updated
Start date July 1, 2017
Est. completion date May 31, 2019

Study information

Verified date July 2020
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, pilot, single center, open-label study in patients with metastatic neuroendocrine tumor. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive a one-time administration of 90Y-DOTA-TOC via the hepatic artery.

Participants in the correlative sub-study will receive 68Ga-DOTA-TOC concurrent with the 90Y-DOTA-TOC dose, and undergo additional imaging and assessment.


Description:

Prior to the procedure, the patient will be instructed to fast overnight. Upon arrival to the hospital intravenous (IV) access will be placed, and Additionally, a scopolamine patch may be placed the night prior to treatment. Additionally a Foley catheter will be placed.

Starting 30 minutes prior to the administration of 90Y-DOTA-TOC, an amino acid solution will be administered via IV. An angiographic catheter will be directed under fluoroscopic guidance to the appropriate location in the hepatic artery.

The 90Y-DOTA-TOC dose will be administered over thirty minutes via the hepatic arterial catheter in an outpatient setting.

Ten patients also enrolled in the correlative sub-study will receive 68Ga-DOTA-TOC concurrent with the therapeutic dose and 90 minutes after treatment, these patients will be imaged 90 minutes after treatment using a Positron Emission Tomography (PET) combined with Computerized tomography (CT) (PET/CT) and the following day using Positron Emission Tomography (PET) combined with magnetic resonance imaging (MRI) (PET/MR).

All study participants will be followed up on protocol for six months for evaluation of toxicity and response to treatment.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date May 31, 2019
Est. primary completion date May 31, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Biopsy proven neuroendocrine tumor, which is somatostatin receptor positive as demonstrated on somatostatin receptor Positron Emission Tomography (PET).

1. All sites or origin are eligible.

2. Functional and nonfunctional tumors are allowed. 2. Hepatic metastases on imaging meeting the following criteria:

a. Liver-only or liver-dominant metastases, defined as: i. At least 10% liver parenchyma replacement by tumor, but less than 70% replacement of the hepatic parenchyma by tumor.

1. For the imaging sub-study: at least one liver lesion must measure greater than 2 cm in size 2. For the imaging sub-study: treatment must only be performed using a single dose, and so arterial variant anatomy that would result in a split treatment will not be allowed ii. And, progression of the liver metastases demonstrated within the past twelve months defined as either:

1. Appearance of any new liver lesion or

2. 20% increase in size of at least one liver lesion. iii. Presence of low-volume extrahepatic lesions (including primary tumor) is allowed if they are stable and asymptomatic.

b. SUVmax on 68Ga-DOTA-TOC PET of the liver metastases two times greater than the adjacent liver parenchyma.

3. Not a candidate for surgical debulking.

4. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2

5. Age > 18.

6. Ability to understand a written informed consent document, and the willingness to sign it.

Exclusion Criteria:

1. Patients not capable of getting PET study due to weight, claustrophobia, or inability to lie still for the duration of the exam.

a. For patients in the imaging correlate sub-study: contraindication for undergoing MRI based on University of California, San Francisco (UCSF) Radiology guidelines.

2. Contraindication to hepatic arteriography (e.g. hepatic artery dissection and/or thrombosis, uncorrectable coagulopathy, severe allergy to iodinated contrast, severe vascular disease precluding safe hepatic artery catheterization).

3. Any patient receiving treatment with short-acting octreotide, which cannot be interrupted for 48 hours before and 24 hours after the administration of 90Y-DOTA-TOC, or any patient receiving treatment with octreotide long-acting release (LAR) or lanreotide, which cannot be interrupted for at least 4 weeks before the administration of 90Y-DOTA-TOC.

a. Concurrent somatostatin receptor analog (SSA) allowed if progression has been documented and the SSA dose has been stable for at least two months. Long-acting SSA cannot be given within four weeks of treatment and short-acting SSA cannot be given with 48 hours of treatment. SSA therapy can restart one day after treatment.

4. Interferon, everolimus (mTOR-inhibitors), sunitinib or other systemic therapies within 4 weeks prior to enrollment. Bevacizumab within 6 weeks prior to enrollment.

5. Any liver directed treatment (surgery, radioembolization, chemoembolization, chemotherapy and radiofrequency ablation) within 12 weeks prior to enrollment.

6. Any external beam radiation treatment for hepatic disease. Prior external beam radiation therapy to more than 25% of the bone marrow.

a. Prior systemic PRRT treatment is allowed, if it was performed at least six months prior.

7. Pregnancy or lactation. Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation

8. Impaired liver function

1. aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase (SGOT)) / alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase (SGPT)) > 3 x upper limit of normal (ULN).

2. Total bilirubin >1.5 x ULN

3. Serum albumin <3.0 g/dL unless prothrombin time is within the normal range.

4. Thrombosis of the main portal vein

5. Clinical evidence of ascites (trace ascites on imaging acceptable).

9. Impaired bone marrow reserve

1. Hb concentration < 8.0 g/dL;

2. Total White Blood Cell count (WBC) <2x109/L (2000/mm3);

3. Platelets <75x109/L (75x103/mm3).

10. Creatinine clearance <50 mL/min calculated by the Cockroft Gault method.

11. Known intracranial metastases.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
90Y-DOTA-TOC
Starting 30 minutes prior to the administration of 90Y-DOTA-TOC, amino acid solution will be administered via IV, and will continue through the PRRT procedure. An angiographic catheter will be inserted under fluoroscopic guidance to the appropriate location in the hepatic artery. 90Y-DOTA-TOC will be administered via the hepatic arterial catheter.
68Ga-DOTA-TOC
In the sub-study, 10 patients will receive 68Ga-DOTA-TOC concurrent with the 90Y-DOTA-TOC dose and 90 minutes after treatment, these patients will be imaged using a PET/CT. The following day, patients enrolled in the sub-study will undergo a PET/MRI.

Locations

Country Name City State
United States University of California, San Francisco San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
Thomas Hope

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Response Rate (ORR) Based on change in size of hepatic lesions three and six months after treatment with IA 90Y-DOTA-TOC using RECIST criteria. Over the duration of the study, which is estimated to be approximately 36 months
Primary Incidence of Treatment-Related Adverse Events [Safety] Based on laboratory evaluation and CTCAE 4.0 criteria. Over the duration of the study, which is estimated to be approximately 36 months
Secondary Change in SUVmax between pre-treatment IV 68Ga-DOTA-TOC PET and treatment IA 68Ga-DOTA-TOC. Data from patients in the imaging correlate sub-study only Over the duration of the study, which is estimated to be approximately 36 months
Secondary Correlation between uptake on IA 68Ga-DOTA-TOC PET/CT compared to 24-hour post-treatment IA 90Y-DOTA-TOC PET/MRI. Data from patients in the imaging correlate sub-study only Over the duration of the study, which is estimated to be approximately 36 months
See also
  Status Clinical Trial Phase
Recruiting NCT04837885 - Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases Phase 2
Completed NCT00789841 - Gastrointestinal Motility in Patients With Neuroendocrine Tumors N/A
Recruiting NCT05069220 - 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor Early Phase 1
Completed NCT05816720 - Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
Active, not recruiting NCT04400474 - Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study Phase 2
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Completed NCT01849523 - Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study N/A
Recruiting NCT01448083 - Heart/Mediastinal Ratio Study for Potential Equivalence of Heart/Mediastinal Ratios at One and Two Hours to the Traditional Heart/Mediastinal Ratio Obtained at Four Hours N/A
Completed NCT00804336 - Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors Phase 1
Active, not recruiting NCT02092714 - Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors
Terminated NCT04073017 - Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency N/A
Completed NCT00434109 - Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization Phase 2
Completed NCT02481804 - Optimal Feeding for NET Patients N/A
Completed NCT02472678 - Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor N/A
Completed NCT02147106 - Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study
Completed NCT00165230 - Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors Phase 2
Active, not recruiting NCT03012789 - Surgical Intervention and the NETest N/A
Not yet recruiting NCT02038738 - 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors Phase 1/Phase 2
Completed NCT01024387 - AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Phase 2
Terminated NCT00227617 - Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Phase 2/Phase 3